Abstract:Abstract Despite the advances in precision oncology, genomic approaches have not significantly improved outcomes for high grade gliomas (HGGs) as once was anticipated. Recurrent HGG pose even greater therapeutic challenge. The integration of functional precision medicine (FPM), in which drugs screens are performed on live tissue, into clinical routine practice presents a promising alternative by offering personalized treatments based on the unique characteristics of the patient’s tumor. Here, we present our institutional experience of integrating a spheroid-based drug screening assay (3D PredictTM Glioma) in the treatment management of HGG patients to evaluate its feasibility and efficacy as a therapeutic tool in a clinical setting. We also sought to determine factors that related to assay success. Tissue from intracranial lesions of patients with presumed HGG and planned surgical resection at our institution were collected for ex vivo 3D cell culture and challenged with 12 drug agents to determine patient-specific response parameters. The impact of potential variables, such as ki67, tumor pathology, and shipment timing, on the assay’s success was evaluated. Clinical correlation was established between ex vivo response and clinical response in HGG patients. 57 samples, including 24 upfront HGGs, 32 recurrent HGGs, and one medulloblastoma, were sent for spheroid formation and drug testing. In total, 57.9% (33/57) or 23% (13/57) of the assays were successful and resulted in complete or partial functional profiling data, respectively. We conducted a multivariable analysis of our cohort to determine which variables (i.e. tumor volume sent, ki-67 proliferation index, tumor percentage determined by DNA sequencing by Tempus Lab, recurrent status, sample shipment time) were predictive of assay success. The only variable significantly associated with assay success was tumor percentage with samples comprised of >70% tumor leading to assay success, 40%-70% leading to 60% chance of success, and <40% having 0% success. Among 46 patients with partial or complete assay success, 26 patients (56.5%) had a targetable mutation and 17/26 yielded a moderate or full response to one or more of their corresponding targeted drugs in the assay. Treatments were newly administered or altered from prior treatments in 40/57 patients (70%) based on FPM results. Our study demonstrates the technical feasibility of incorporating FPM approaches in the development of treatment regimens for patients with HGG. Success was correlated to tumor percentage present in the sample which indicates intraoperative communication between surgeon and pathologist can lead to improved assay results. Our institutional protocol demonstrates that Integrating FPM into routine clinical practice is possible and can serve as a valuable guide in the refinement of therapeutic recommendations for HGG patients. Citation Format: Grace Guzman, Sahana Bettadapura, William Jeremy Shelton-Correa, Taylor Brooks, Melissa Rayner, Christopher Wardell, Analiz Rodriguez. Integration of functional precision medicine assay for high grade glioma management: A single institution experience [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 953.

Functional precision medicine assay for recurrent meningioma: a proof of principle. Illustrative case

Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma

Abstract 953: Integration of functional precision medicine assay for high grade glioma management: A single institution experience

Application of Drug Testing Platforms in Circulating Tumor Cells and Validation of a Patient-Derived Xenograft Mouse Model in Patient with Primary Intracranial Ependymomas with Extraneural Metastases

Abstract 2553: Functional precision medicine as a valid tool in glioblastoma clinical practice

Personalized Medicine for Meningiomas: Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities to HDAC1/2i Panobinostat

206 Spinal Meningioma: An Institutional Case Series With Preliminary Results of Molecular Profiling

MDB-38. COMPUTATIONAL DRUG SENSITIVITY PREDICTS MEDULLOBLASTOMA SUBGROUP-SPECIFIC THERAPEUTICS

Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Screening in NF2-associated Schwannoma.

BIOM-35. A NEW PRECISION-MEDICINE APPROACH TO PREDICT TUMOR TREATMENT RESPONSE IDENTIFIES IN GLIOBLASTOMA A 17 GENE SIGNATURE PROGNOSTIC OF TMZ RESPONSE AND SURVIVAL WITH ROBUST PREDICTIVE VALUE

Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas

CBX7 Reprograms Metabolic Flux to Protect Against Meningioma Progression by Modulating the USP44/c-MYC/LDHA Axis.

OS8.7 Targeting Pi3k-Akt-mTOR and MAPKinase pathways in aggressive meningiomas: in vitro study

Biom-50. Serial Intracranial Cerebrospinal Cell-Free Dna For Disease Monitoring In Patients With Gliomas

379 Meningioma Molecular Groups Predict Response to Adjuvant Radiotherapy Following Surgery

Abstract 2346: Meningioma molecular classification predict response to surgical resection and adjuvant radiotherapy: An integrated clinicomolecular analysis

Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis.

Ctim-31. Preliminary Results Of A Phase Ii Study Of Stereotactic Radiosurgery In Conjunction With The Pd-1 Inhibitor Pembrolizumab For The Treatment Of Recurrent High-Grade Meningioma

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma

The CREB-binding Protein Inhibitor ICG-001: a Promising Therapeutic Strategy in Sporadic Meningioma with NF2 Mutations.

Radt-23. Molecular Profiling Of Gliomas: Insights Into Radionecrosis And Pseudoprogression Through Next-Generation Sequencing